TDP-43 Potentiates Alpha-synuclein Toxicity to Dopaminergic Neurons in Transgenic Mice by Tian, Tian et al.
Int. J. Biol. Sci. 2011, 7 
 
 
http://www.biolsci.org 
234 
I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   B Bi io ol lo og gi ic ca al l   S Sc ci ie en nc ce es s   
2011; 7(2):234-243 
Research Paper 
TDP-43 Potentiates Alpha-synuclein Toxicity to Dopaminergic Neurons in 
Transgenic Mice 
Tian Tian1, 2*, Cao Huang1*, Jianbin Tong1, Ming Yang1, Hongxia Zhou1, Xu-Gang Xia1 
 
1.  Department of Pathology, Anatomy & Cell Biology, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA 
19107, USA 
2.  Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan Province 410008, China  
*These authors contributed equally to this work. 
 Corresponding author: H.Z. (Hongxia.zhou@jefferson.edu) or X.G.X (xugang.xia@jefferson.edu) 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2011.02.22; Accepted: 2011.03.03; Published: 2011.03.04 
Abstract 
TDP-43 and α-synuclein are two disease proteins involved in a wide range of neurodegen-
erative diseases. While TDP-43 proteinopathy is considered a pathologic hallmark of sporadic 
amyotrophic lateral sclerosis and frontotemporal lobe degeneration, α-synuclein is a major 
component of Lewy body characteristic of Parkinson’s disease. Intriguingly, TDP-43 protei-
nopathy also coexists with Lewy body and with synucleinopathy in certain disease conditions. 
Here we reported the effects of TDP-43 on α-synuclein neurotoxicity in transgenic mice. 
Overexpression  of mutant  TDP-43  (M337V  substitution)  in  mice  caused  early death  in 
transgenic founders, but overexpression of normal TDP-43 only induced a moderate loss of 
cortical neurons in the transgenic mice at advanced ages. Interestingly, concomitant over-
expression of normal TDP-43 and mutant α-synuclein caused a more severe loss of dopa-
minergic neurons in the double transgenic mice as compared to single-gene transgenic mice. 
TDP-43 potentiated α-synuclein toxicity to dopaminergic neurons in living animals.  Our 
finding  provides  in  vivo  evidence  suggesting  that  disease  proteins  such  as  TDP-43  and 
α-synuclein may play a synergistic role in disease induction in neurodegenerative diseases. 
Key  words:  TDP-43;  alpha-synuclein;  mice;  dopaminergic  neuron;  Parkinson’s  disease;  fronto-
temporal lobe degeneration, genetic model 
1. Introduction 
TAR  DNA-binding  protein  43  (TDP-43)  is  a 
conserved  ribonucleoprotein  with  diverse  functions 
as  exemplified  by  the  ability  to  regulate  gene  tran-
scription,  mRNA  splicing,  and  RNA  stability  (1-6). 
While its physiological functions remain to be eluci-
dated,  TDP-43  translocates  to  the  cytoplasm  and 
forms ubiquitinated aggregates in neurodegenerative 
diseases including amyotrophic lateral sclerosis (ALS) 
and frontotemporal lobe degeneration (FTLD) (7-10). 
TDP-43  proteinopathy,  a  hallmark  of  sporadic  ALS 
and FTLD, is also observed in the other neurodegen-
erative diseases such as Parkinson’s disease (PD) and 
Alzheimer’s  disease  (11-13).  Neurodegenerative  dis-
eases  share  some  features  in  the  pathogenesis  and 
pathology. Most cases of the diseases are sporadic and 
only a small proportion of them have a clear genetic 
cause. A neurodegenerative disease is characterized 
by a selected group of neurons preferably affected at 
early disease stages, but it often affects a wide range 
of different neurons at advanced disease stages. For 
example, heterogeneous neuropathology is observed 
in sporadic ALS at advanced disease stages  (14-16), 
although motor neurons are preferably affected in the 
disease at early disease stages. TDP-43 proteinopathy Int. J. Biol. Sci. 2011, 7 
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is direct evidence supporting that neurodegenerative 
diseases may be pathogenically interrelated. 
While mutation in TDP-43 is linked to ALS and 
FTLD (17-21), mutation of the α-synuclein gene is as-
sociated with PD (22-26). Overexpression of TDP-43 
with or without pathogenic mutation causes a broad 
neurodegeneration in rodents (27-32), suggesting that 
normal TDP-43 of elevated expression is neurotoxic. 
Overexpression of TDP-43 in the substantia nigra in-
duces  dopaminergic  neuron  death  (33),  suggesting 
that  TDP-43  neurotoxicity  is  not  restricted  to  the 
neurons preferably affected in ALS and FTLD. Over-
expression  of  pathogenically  mutated  α-synuclein 
causes dopaminergic neuron death in transgenic mice 
at  advanced  ages  (34).  Neurodegenerative  diseases 
are commonly thought of multifactorial pathogenesis. 
To test this hypothesis, we examined whether TDP-43 
potentiates  α-synuclein  toxicity  to  dopaminergic 
neurons  in  transgenic  mice.  Transgenic  overexpres-
sion of the normal TDP-43 caused a significant loss of 
neurons in the frontal cortex, but not in the substantia 
nigra  pars  compacta  (SNpc).  When  normal  TDP-43 
and  mutant  α-synuclein  were  overexpressed  simul-
taneously  in  the  dopaminergic  neurons,  a  dramatic 
loss  of  the  neurons  was  detected  in  the  SNpc  of 
transgenic mice. Our results suggest that neurotoxic 
factors such as TDP-43 and α-synuclein may play a 
synergistic role in the pathogenesis of neurodegener-
ative diseases. 
2. Materials and Methods 
Animal experiments 
Animal  use  followed  NIH  guidelines  and  the 
animal use protocol was approved by the Institutional 
Animal Care and Use Committees at Thomas Jeffer-
son University. As described in our publication (32, 
35), the cDNA of normal human TDP-43 and its mu-
tant form (M337V substitution) was created by PCR 
and was cloned into CAG expression vector. Linear-
ized transgene constructs were injected into the pro-
nuclei of fertilized eggs of C57BL/6J mice. Transgenic 
mice  were  identified  by  PCR  amplification  of  the 
human TDP-43 transgene with the following primers: 
5’-TGCGGGAGTTCTTCTCTCAG-3’  (forward)  and 
5’-AGCCACCTGGATTACCACCA-3’  (reverse).  Du-
al-mutant α-synuclein transgenic mice were received 
from Dr. Richfield and were genotyped by PCR anal-
ysis as described in the original publications (34, 36). 
All transgenic mice were maintained on C57BL6 ge-
nomic background. 
Mouse psychomotor activity was  measured by 
Rotarod  test  as  described  previously  (35,  37).  Mice 
were tested on a rotating Rotarod (Med Associates) 
twice a week since three months of age. On a testing 
day, a mouse was tested three times separated by 10 
minutes of rest and was allowed to run on a rotating 
Rotarod with accelerated speeds for a maximal period 
of five minutes. The average time of three tests was 
calculated as the latency to fall from rotating rotarod. 
Immunoblotting 
Mouse tissues were homogenized in RAPI buffer 
supplied with protease inhibitors (Promega). Tissue 
lysates were cleared by centrifugation and proteins in 
cleared lysates were measured by BCA assay (Pierce). 
Total proteins of 25 µg in each lysate were separated 
on  10%  SDS-PAGE  and  were  blotted  onto  PVDF 
membrane. The immunoreactivity of both human and 
mouse TDP-43 was detected with a polyclonal anti-
body (1: 500; Proteintech) and the immunoreactivity 
of human TDP-43 was detected with a mouse mono-
clonal antibody (1: 1000; Abnova, 2E2-D3). Compara-
ble loading of total proteins among samples was es-
timated  by  probing  the  same  membranes  with  a 
mouse  monoclonal  antibody  recognizing  mouse 
glyceraldehyde-3-phosphatedehydrogenase  (1:  2000; 
Abnova).  Immunoreactivity  was  visualized  by  ECL 
reaction (Pierce). 
Toluidine blue staining 
As described in our publication (32), the ventral 
and  dorsal  nerve  roots  of  TDP-43  transgenic  mice 
were  examined  for  axon  degeneration  by  toluidine 
blue staining. Mice were anesthetized and perfused 
with a mixture of 4% PFA and 2% glutaraldehyde in 
0.1 M phosphate buffer (pH 7.4). The L4 ventral and 
dorsal roots were removed and post-fixed in the same 
fixative at 4°C overnight. The roots were further fixed 
in  1%  osmium  tetroxide  in  0.1  M  phosphate  buffer 
(pH  7.4) for  1  h.  The  well-fixed  tissues  were  dehy-
drated in graded ethanol and were embedded in Epon 
812 (Electron Microscopic Sciences, Fort Washington, 
PA).  Nerve  roots  were  transversely  cut  into  1 
µm-thick  sections.  Axons  in  the  nerve  roots  were 
examined in the semi-thin sections under a light mi-
croscope (Nikon 80i). 
Immunostaining and histology 
Mouse tissues were fixed in 4% PFA and were 
cryopreserved in 30% sucrose. On a Cryostat, mouse 
brain  was  cut  into  coronal  sections  of  20  µm  and 
mouse spinal cord was cut into traverse sections of 15 
µm. Human TDP-43 immunoreactivity was detected 
by incubating tissue sections with a monoclonal an-
tibody  specific  for  human  TDP-43  (1:  500;  Abnova, 
2E2-D3)  and  was  visualized  using  an  ABC  kit  in 
combination  with  diaminobenzidine  (Vector).  Im-
munostained  sections  were  lightly  counterstained Int. J. Biol. Sci. 2011, 7 
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with  hematoxylin  to  display  the  nuclei.  Dou-
ble-labeling  immunofluorescence  staining  was  per-
formed  as  described  previously  (32).  The  following 
antibodies were used for immunofluorescence stain-
ing: mouse monoclonal antibody to human TDP-43 (1: 
500; Abnova, 2E2-D3), chicken antibody to ubiquitin 
(1: 1000; Sigma), rabbit antibody to tyrosine hydrox-
ylase (TH; Pel-Freez; 1:1000), and mouse monoclonal 
antibody  to  human  α-synuclein  (1:  1000;  Abcam, 
4B12).  Frozen  sections  of  the  gastrocnemius  muscle 
were stained  with  hematoxylin and eosin (H&E) to 
display tissue structures. 
Stereological cell counting 
As described in our publication (38), the number 
of dopaminergic neurons in the SNpc was estimated 
by stereological cell counting. PFA-fixed mouse mid-
brain was cut on a Cryostat into four series of sections 
and every fourth section was immunostained for TH. 
The number of TH-positive neurons in the SNpc was 
estimated with fractionator-based stereology software 
(Stereologer), which was run on a PC computer at-
tached to a Nikon 80i microscope with a motorized 
XYZ stage (Prior). The number of cortical neurons in 
the frontal cortex was also estimated by stereological 
cell counting as described previously (39). 
3. Results 
Overexpression of a mutant TDP-43 causes early 
death in transgenic founders 
To  develop  a  genetic  animal  model  for 
TDP-43-linked ALS and FTLD, we created transgenic 
mice expressing the human TDP-43 with or without a 
pathogenic mutation (Fig. 1).  
 
 
Figure 1: Expression of human TDP-43 in transgenic mice. a, Schematic shows the structure of human TDP-43 
transgene. The transgene constructs consist of the CAG promoter, the first noncoding exon and the first intron of the 
chicken beta actin gene, the human TDP-43 cDNA with or without pathogenic mutation (M337V substitution), and the three 
repeats of SV40 polyadenylation signal. b, PCR analysis identified transgenic founders carrying the normal or the mutant 
(M337V) human TDP-43 transgene (hTDP-43). C+: positive control; C-: negative control. c, Immunoblotting detected a 
robust expression of human TDP-43 in the forebrain of transgenic founder mice. NG: nontransgenic mouse brain. d, Photo 
showing a transgenic founder mouse and its nontransgenic littermate (NG) at 7 days of age. e, Immunoblotting detected a 
robust expression of human TDP-43 in the central nerve system of normal TDP-43 transgenic mice. Each lane was loaded 
with 25 µg of total protein. The same membrane was first probed with a TDP-43 antibody recognizing both human and 
mouse TDP-43 and was then probed with a GAPDH antibody. Muscle: skeletal muscle; hippo: hippocampus. Int. J. Biol. Sci. 2011, 7 
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The  hybrid  promoter  CAG  is  shown  to  drive 
transgene  expression  robustly  and  ubiquitously  in 
rodents  (35,  40,  41),  and  thus  it  was  used  to  drive 
TDP-43 transgenes in mice (Fig. 1a). We chose M337V 
substitution as an example of TDP-43 mutations be-
cause  this  mutant  causes  typical  ALS  with  a  mid-
dle-age  onset  of  symptoms  (18).  We  obtained  four 
transgenic  founders  expressing  mutant  TDP-43M337V 
and one founder expressing normal TDP-43 (Fig. 1). 
These transgenic founders were born of normal sizes; 
three  TDP-43M337V  founders  lost  mobility  soon  after 
birth and died within 10 days of birth (Fig. 1d). One 
TDP-43M337V female founder lived to 4 months of age, 
but it was infertile and died shortly after immobility 
was observed. We examined this mutant founder for 
neuronal and axonal degeneration in the spinal cord 
and nerve roots, but did not detect a significant loss of 
spinal motor neurons or motor axons. Similar to our 
finding  in  transgenic  rats  (32),  constitutive  overex-
pression  of  mutant  TDP-43  in  mice  caused  severe 
phenotypes  in  transgenic  founders,  preventing 
transgenic lines from establishment. By contrast, the 
transgenic  founder  overexpressing  normal  TDP-43 
was healthy and fertile. 
To expand the normal TDP-43 transgenic mouse 
colony,  we  crossed  the  transgenic  founder  with 
C57BL6/J  mice  newly  purchased  from  Jackson  La-
boratories. Unexpectedly, some male transgenic mice 
of the first three generations died within a week after 
immobility  was  observed.  No  detectable  phenotype 
was observed in TDP-43 transgenic mice beyond the 
fourth generation. We examined the sick mice and did 
not detect a degeneration of spinal motor neurons or 
motor  axons.  The  copy  number  of  human  TDP-43 
transgene was unaltered through mouse generations 
examined  (all  22  copies).  We  maintained  a  C57BL6 
colony  derived  from  a  mating  pair  that  was  pur-
chased from the Jackson Laboratories four years ago, 
and  we  created  TDP-43  transgenic  mice  on  the  ge-
nomic background of this mouse colony. The genomic 
background of TDP-43 transgenic mice could thus be 
considered congenic, but unidentified environmental 
or genetic factors may alter phenotypic expression in 
our TDP-43 transgenic mice. 
Overexpression of the normal TDP-43 causes 
cortical neuron degeneration in transgenic mice 
TDP-43-positive inclusion is a hallmark of spo-
radic ALS and FTLD (42, 43), suggesting that TDP-43 
may be involved in the pathogenesis of the sporadic 
diseases. We used TDP-43 transgenic mice of the sixth 
generation  for  the  following  experiments.  A  robust 
expression  of  human  TDP-43  was  detected  in  the 
brain,  spinal  cord,  and  skeletal  muscles  of  TDP-43 
transgenic mice (Figs. 1e, 2b, 3b, and 3c), but not in the 
tissues of nontransgenic controls (Figs. 2a and 3a). On 
a  homogenous  genomic  background,  TDP-43  trans-
genic  mice did  not develop abnormality  in psycho-
motor activity by age of one year (Fig. 2c). Accord-
ingly,  TDP-43  transgenic  mice  did  not  develop  de-
tectable pathology in the spinal motor neurons (Fig. 
2d-2e),  in  the  dorsal  and  ventral  nerve  roots  (Fig. 
2f-2i), and in the skeletal muscles (Fig. 2j-2k). Muta-
tion of  TDP-43 is also linked to FTLD  (44). Altered 
expression of normal TDP-43 may affect cortical neu-
rons in transgenic animals (32). We assessed cortical 
and  hippocampal  neurons  by  an  unbiased  meth-
od—stereological cell counting and detected a signif-
icant loss of cortical neurons in the transgenic mice at 
advanced ages (Fig. 3d-3i). Ubiquitinated TDP-43 ag-
gregates are common to sporadic ALS and FTLD (42, 
43). We examined these pathologies in TDP-43 trans-
genic  mice,  but  did  not  detect  typical  TDP-43  or 
ubiquitin aggregates in the brain and spinal cord of 
the aged mice (Fig. 4a-4l). Consistent with our find-
ings  in  TDP-43  transgenic  rats  (32),  ubiquitin  and 
TDP-43 aggregation is not essential to neuronal death. 
Overexpression of normal TDP-43 potentiates 
alpha-synuclein toxicity to dopaminergic neurons 
in transgenic mice 
TDP-43  proteinopathy  is  observed  in  a  wide 
range  of  neurodegenerative  diseases  including  PD 
(12,  13).  Transient  overexpression  of  TDP-43  in  the 
substantia  nigra  causes  dopaminergic  neuron  death 
(33). Alpha-synuclein is a major component of Lewy 
body characteristic of PD and pathogenic mutation of 
α-synuclein is implicated in PD pathogenesis (22-26). 
We  further  examined  whether  TDP-43  modifies 
α-synuclein toxicity in the double transgenic mice. In 
TDP-43 transgenic mice, a substantial number of do-
paminergic  neurons  expressed  human  TDP-43  as 
shown  by  double-labeling  immunofluorescence 
staining  (Fig.  5a-5f).  Overexpression  of  human 
TDP-43 alone did not induce a significant loss of do-
paminergic neurons in the transgenic mice (Fig. 5q). 
We  then  crossed  TDP-43  transgene  onto  a  mutant 
α-synuclein transgenic background (Fig. 5g-5l). Pre-
vious  study  showed  that  overexpression  of  mutant 
α-synuclein causes a significant loss of dopaminergic 
neurons in male mice at advanced ages (34); however, 
we did not detect a significant loss of dopaminergic 
neurons  in  the  mutant  α-synuclein  transgenic  mice 
though a trend of neuronal loss was observed (Fig. 
5q). Our result does not contradict the previous study 
because  we  examined  three  male  and  three  female 
α-synuclein  transgenic  mice.  Male  mice  appeared 
more  sensitive  to  mutant  α-synuclein  toxicity  than Int. J. Biol. Sci. 2011, 7 
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female  mice.  In  our  study,  statistical  significance 
might be obscured by a limited number of animals 
and a mixture of male and female mice. Interestingly, 
simultaneous overexpression of normal TDP-43 and 
mutant  α-synuclein  caused  a  significant  loss  of  do-
paminergic  neurons  in  the  transgenic  mice  as  com-
pared to either single transgenic control (Fig. 5m-5q), 
suggesting that TDP-43 potentiated α-synuclein neu-
rotoxicity. 
 
 
 
 
Figure 2: No detectable impairment in the motor system of TDP-43 transgenic mice at advanced ages. a, b, 
Immunostaining detected human TDP-43 only in the TDP-43 transgenic mouse (hTDP43), but not in its nontransgenic 
control (NT). Cross sections of lumbar spinal cord were immunostained with a monoclonal antibody recognizing human 
TDP-43 and the ventral horns of lumbar cords were photographed. c, Rotarod test revealed no difference in psychomotor 
activity between the TDP-43 transgenic mice (hTDP43) and the nontransgenic littermates (NT). Each group consisted of 8 
mice with equal sex composition. d, e, Cresyl violet staining revealed no significant loss of motor neurons in the  lumbar 
cords of TDP-43 transgenic mice. f-i, Toluidine blue staining showed the structure of the L4 ventral roots (f, g) and the L4 
dorsal roots (h, i) in TDP-43 transgenic mice and their nontransgenic littermates at the age of 11 months. j, k, H&E staining 
revealed no atrophy of skeletal muscles in the TDP-43 transgenic mice. Scale bars: a-b and f-k, 20 µm; d-e, 50 µm. Int. J. Biol. Sci. 2011, 7 
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Figure 3: A significant loss of cortical neurons in the frontal cortex of TDP-43 transgenic mice at advanced 
ages. a-c, Immunostaining revealed a robust expression of human TDP-43 in the cortex and dentate gyrus of TDP-43 
transgenic mouse, but not in the cortex of a nontransgenic control (NT). d-g, Cresyl violet staining showed the neurons in 
the frontal cortex (d, e) and hippocampus (f, g). Scale bars: a-e, 20 µm; and f-g, 50 µm. h, i, Stereological cell counting 
revealed a significant loss of neurons in the frontal cortex, but not in the dentate gyrus, of TDP-43 transgenic mice. Mice 
were 10-12 months old. Data are means + SD (n = 5). * indicates p < 0.05. 
 
Figure 4: Ubiquitin 
inclusion  unde-
tectable in TDP-43 
transgenic mice at 
advanced ages. a-l, 
Double-labeling  flu-
orescence  staining 
revealed no ubiquitin 
inclusion  in 
TDP-43-overexpressi
ng cells in transgenic 
mice at 10 months of 
age.  Tissue  sections 
from  TDP-43  trans-
genic mice (hTDP43) 
or the nontransgenic 
controls  (NT)  were 
immunostained  for 
human  TDP-43  and 
mouse  ubiquitin.  All 
scale bars: 20 µm. Int. J. Biol. Sci. 2011, 7 
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Figure 5: Synergistic effects of TDP-43 and mutant alpha-synuclein on dopaminergic neurons in transgenic 
mice. a-f, Double-fluorescence labeling revealed a substantial expression of human TDP-43 in the dopaminergic neurons of 
human TDP-43 transgenic mice (hTDP43), but not in the neurons of nontransgenic mice (NT). Coronal sections of the 
midbrain were simultaneously immunostained for human TDP-43 and mouse tyrosine hydroxylase (TH, a marker of do-
paminergic  neurons).  g-l,  double-labeling  fluorescence  staining  detected  a  robust  expression  of  a  mutant  human  al-
pha-synuclein (hSYN) in the dopaminergic neurons of hSYN transgenic mice, but not in the neurons of nontransgenic mice 
(NT). m-p, Representative photos of low (m, o) or high (n, p) magnification showing dopaminergic neurons in the substantia 
nigra of TDP-43 single (m, n) and TDP-43/hSYN double (o, p) transgenic mice. Scale bars: a-l, n and p, 20 µm; m, o, 80 µm. 
q, Stereological cell counting revealed a significant loss of dopaminergic neurons (TH-positive) in the TDP-43 and al-
pha-synuclein double transgenic mice (SYN/TDP) as compared to nontransgenic (NT) or the single transgenic (hTDP or 
SYN) mice at 10-12 months of age. Data are means + SD (n = 4-6). The symbol * indicates p < 0.05 as compared to SYN or 
hTDP transgenic mice. 
 
 
4. Discussion 
Consistent with our findings in transgenic rats 
(32), pathogenically mutated TDP-43 exhibited higher 
toxicity than the wildtype form when overexpressed 
in  transgenic  mice.  Normal  TDP-43  of  elevated  ex-
pression was sufficient to induce neurotoxicity in vivo. 
Moreover, TDP-43 and mutant α-synuclein synergis-
tically  induced  neurotoxicity  when  concomitantly 
overexpressed in the dopaminergic neurons of trans-
genic  mice,  suggesting  that  neuron  death  is  a  con-
vergent outcome of the toxicity of disease factors in 
neurodegenerative diseases such as PD. 
While  the  nature  of  pathogenic  mutation  in 
TDP-43  remains  largely  unknown,  TDP-43  with 
pathogenic  mutation  or  elevated  expression  is  neu-
rotoxic  in  vitro  and  in  vivo  (28,  45-48).  Pathogenic 
mutation of TDP-43 may cause a gain of function, a 
loss of function, or a dominant negative effect. The 
information available is not sufficient to determine the 
nature of TDP-43 mutation. Silencing of TDP-43 ex-
pression by RNAi induces neuronal death in culture Int. J. Biol. Sci. 2011, 7 
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(49,  50).  Deletion  of  TDP-43  causes  a  defect  at  the 
neuromuscular  junction  in  Drosophila  melanogaster 
(51). Constitutive or temporal deletion of TDP-43 in 
mice induces severe phenotypes (52, 53), underscor-
ing the importance of TDP-43 in cellular function. It 
remains  unclear  whether  neurodegeneration  can  be 
induced by cell-specific deletion of TDP-43 in condi-
tional  knockout  mice.  Forced  overexpression  of  hu-
man  TDP-43  in  mice  deregulates  the  expression  of 
mouse endogenous TDP-43 (27). Since it is not known 
whether  human  TDP-43  can  function  properly  in 
mouse tissues, addition of normal human TDP-43 to 
mouse genome may or may not enhance the functions 
of TDP-43. In addition, transgenic overexpression of 
mutant  TDP-43  is  unable  to  differentiate  a  gain  of 
function  from  a  dominant  negative  effect  because 
both types of mutation can induce disease in trans-
genic animals (54-56). Although a more sophisticated 
model such as a TDP-43 knockin mouse is required 
for determining the natures of TDP-43 mutation, our 
results, along with previous findings (27, 28, 45-48, 50, 
52, 53), suggest a possible gain of function in TDP-43 
mutation. We previously showed that overexpression 
of  normal  TDP-43  does  not  induce  ALS  disease  in 
transgenic  rats  (32).  Consistent  with  our  finding  in 
rats, overexpression of normal TDP-43 in mice failed 
to induce ALS phenotypes. Interestingly, overexpres-
sion of normal TDP-43 caused a significant (though 
moderate)  loss  of  cortical  neurons  in  asymptomatic 
mice at advanced ages. It could not be ruled out that 
overexpression of normal TDP-43 may induce cortical 
neuron degeneration in aged rats. We will examine 
cortical neurons in normal TDP-43 transgenic rats at 
advanced ages in a follow-up study. 
TDP-43 and α-synuclein are involved in a wide 
range  of  neurodegenerative  diseases.  While  TDP-43 
proteinopathy is considered a pathologic hallmark of 
ALS and FTLD (7-10), it also coexists with Lewy pa-
thology that is a characteristic of sporadic PD (57-59). 
Alpha-synuclein is a major component of Lewy body 
and Lewy neurites in PD (57-59). When concomitantly 
overexpressed  in  mice,  TDP-43  and  mutant 
α-synuclein  synergistically  induced  dopaminergic 
neurodegeneration. Our finding is not unexpected as 
TDP-43 and α-synuclein proteinopathy coexist in pa-
tients with neurodegenerative diseases (57-59). Clini-
cally, synucleinopathy is more severe in the cases with 
than in the cases without TDP-43 proteinopathy (60). 
It remains unclear whether and how disease proteins 
(such  as  TDP-43,  α-synuclein,  β-amyloid,  and  tau) 
interact to induce degeneration of selected groups of 
neurons in patients with neurodegenerative diseases. 
Our study has provided in vivo evidence suggesting 
that disease proteins such as TDP-43 and α-synuclein 
may  play  a  synergistic  role  in  disease  induction  in 
neurodegenerative diseases. 
Acknowledgement 
We thank Ms. Dian Wang, Ms. Xiaotao Wei, and 
Ms. Zhen Qu for technical assistance. 
This work is supported by the National Institutes 
of  Health  (NIH)/National  Institute  of  Neurological 
Disorders  and  Stroke  (NS064042  and  NS072113  to 
X.G.X)  and  by  the  National  Institutes  of 
Health/National  Institute  of  Environmental  Health 
Sciences (ES016760 to X.G.X). The content is solely the 
responsibility of the authors and does not necessarily 
represent the official view of the NIH institutes. 
Conflict of Interests 
The authors declare no conflicts of interest. 
References 
1.  Buratti  E,  Brindisi  A,  Giombi  M,  Tisminetzky  S,  Ayala  YM, 
Baralle  FE.  TDP-43  binds  heterogeneous  nuclear 
ribonucleoprotein  A/B  through  its  C-terminal  tail:  an 
important  region  for  the  inhibition  of  cystic  fibrosis 
transmembrane conductance regulator exon 9 splicing. J  Biol 
Chem 2005;280(45):37572-37584. 
2.  Abhyankar  MM,  Urekar  C,  Reddi  PP.  A  novel  CpG-free 
vertebrate  insulator  silences  the  testis-specific  SP-10  gene  in 
somatic  tissues:  role  for  TDP-43  in  insulator  function.  J  Biol 
Chem 2007;282(50):36143-36154. 
3.  Bose  JK,  Wang  IF,  Hung  L,  Tarn  WY,  Shen  CK.  TDP-43 
overexpression enhances exon 7 inclusion during the survival 
of  motor  neuron  pre-mRNA  splicing.  J  Biol  Chem 
2008;283(43):28852-28859. 
4.  Ou  SH,  Wu  F,  Harrich  D,  García-Martínez  LF,  Gaynor  RB. 
Cloning  and  characterization  of  a  novel  cellular  protein, 
TDP-43, that binds to human immunodeficiency virus type 1 
TAR DNA sequence motifs. J Virol 1995;69(6):3584-3596. 
5.  Buratti  E,  Baralle  FE.  Characterization  and  functional 
implications of the RNA binding properties of nuclear factor 
TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem 
2001;276(39):36337-36343. 
6.  Strong  MJ,  Volkening  K,  Hammond  R,  Yang  W,  Strong  W, 
Leystra-Lantz  C,  Shoesmith  C.  TDP43  is  a  human  low 
molecular  weight  neurofilament  (hNFL)  mRNA-binding 
protein. Mol Cell Neurosci 2007;35(2):320-327. 
7.  Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, 
Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de 
Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, et al. TDP-43 
mutations  in  familial  and  sporadic  amyotrophic  lateral 
sclerosis. Science 2008;319(5870):1668-1672. 
8.  Gitcho  MA,  Baloh  RH,  Chakraverty  S,  Mayo  K,  Norton  JB, 
Levitch D, Hatanpaa KJ, White CL, Bigio EH, Caselli R, Baker 
M, Al-Lozi MT, Morris JC, Pestronk A, Rademakers R, et al. 
TDP-43 A315T mutation in familial motor neuron disease. Ann 
Neurol 2008;63(4):535-538. 
9.  Banks GT, Kuta A, Isaacs AM, Fisher EM. TDP-43 is a culprit in 
human neurodegeneration, and not just an innocent bystander. 
Mamm Genome 2008;19(5):299-305. 
10.  Benajiba L, Le Ber I, Camuzat A, Lacoste M, Thomas-Anterion 
C, Couratier P, Legallic S, Salachas F, Hannequin D, Decousus 
M, Lacomblez L, Guedj E, Golfier V, Camu W, Dubois B, et al. 
TARDBP  mutations  in  motoneuron  disease  with Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
242 
frontotemporal  lobar  degeneration.  Ann  Neurol 
2009;65(4):470-473. 
11.  Lippa  CF,  Rosso  AL,  Stutzbach  LD,  Neumann  M,  Lee  VM, 
Trojanowski JQ. Transactive response DNA-binding protein 43 
burden  in  familial  Alzheimer  disease  and  Down  syndrome. 
Arch Neurol 2009;66(12):1483-1488. 
12.  Chanson JB, Echaniz-Laguna A, Vogel T, Mohr M, Benoilid A, 
Kaltenbach  G,  Kiesmann  M.  TDP43-positive  intraneuronal 
inclusions  in  a  patient  with  motor  neuron  disease  and 
Parkinson's disease. Neurodegener Dis 2010;7(4):260-264. 
13.  Markopoulou  K,  Dickson  DW,  McComb  RD,  Wszolek  ZK, 
Katechalidou L, Avery L, Stansbury MS, Chase BA. Clinical, 
neuropathological  and  genotypic  variability  in  SNCA  A53T 
familial Parkinson's disease. Variability in familial Parkinson's 
disease. Acta Neuropathol 2008;116(1):25-35. 
14.  Nishihira Y, Tan CF, Toyoshima Y, Yonemochi Y, Kondo H, 
Nakajima  T,  Takahashi  H.  Sporadic  amyotrophic  lateral 
sclerosis: Widespread multisystem degeneration with TDP-43 
pathology in a patient after long-term survival on a respirator. 
Neuropathology 2009; epub. 
15.  Machida  Y,  Tsuchiya  K,  Anno  M,  Haga  C,  Ito  T,  Shimo  Y, 
Wakeshima T, Iritani S, Ikeda K. Sporadic amyotrophic lateral 
sclerosis  with  multiple  system  degeneration:  a  report  of  an 
autopsy  case  without  respirator  administration.  Acta 
Neuropathol 1999;98(5):512-515. 
16.  Tsuchiya K, Sano M, Shiotsu H, Akiyama H, Watabiki S, Taki K, 
Kondo  H,  Nakano  I,  Ikeda  K.  Sporadic  amyotrophic  lateral 
sclerosis  of  long  duration  mimicking  spinal  progressive 
muscular atrophy exists: additional autopsy case with a clinical 
course of 19 years. Neuropathology 2004;24(3):228-235. 
17.  Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey 
BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, 
Salachas  F,  Pradat  PF,  Camu  W,  Meininger  V,  Dupre  N, 
Rouleau GA. TARDBP mutations in individuals with sporadic 
and  familial  amyotrophic  lateral  sclerosis.  Nat  Genet 
2008;40(5):572-574. 
18.  Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, 
Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de 
Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, et al. TDP-43 
mutations  in  familial  and  sporadic  amyotrophic  lateral 
sclerosis. Science 2008;319(5870):1668-1672. 
19.  Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, 
Elman LB, Clay D, Wood EM, Chen-Plotkin AS, Martinez-Lage 
M, Steinbart E, McCluskey L, Grossman M, Neumann M, Wu 
IL, et al. TARDBP  mutations in amyotrophic lateral  sclerosis 
with TDP-43 neuropathology: a genetic and histopathological 
analysis. Lancet Neurol 2008;7(5):409-416. 
20.  Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, 
Stewart H, Kelley BJ, Kuntz K, Crook RJ, Sreedharan J, Vance C, 
Sorenson  E,  Lippa  C,  Bigio  EH,  et  al.  Novel  Mutations  in 
TARDBP  (TDP-43)  in  Patients  with  Familial  Amyotrophic 
Lateral Sclerosis. PLoS Genet 2008;4(9):e1000193. 
21.  Benajiba L, Le Ber I, Camuzat A, Lacoste M, Thomas-Anterion 
C, Couratier P, Legallic S, Salachas F, Hannequin D, Decousus 
M, Lacomblez L, Guedj E, Golfier V, Camu W, Dubois B, et al. 
TARDBP  mutations  in  motoneuron  disease  with 
frontotemporal  lobar  degeneration.  Annals  of  Neurology 
2009;65:470-474. 
22.  Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, 
Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, 
Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, 
Johnson  WG,  et  al.  Mutation  in  the  alpha-synuclein  gene 
identified  in  families  with  Parkinson's  disease.  Science 
1997;276(5321):2045-2047. 
23.  Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, 
Przuntek H, Epplen JT, Schols L, Riess O. Ala30Pro mutation in 
the gene encoding alpha-synuclein in Parkinson's disease. Nat 
Genet 1998;18(2):106-108. 
24.  Singleton  AB,  Farrer  M,  Johnson  J,  Singleton  A,  Hague  S, 
Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, 
Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, et al. 
alpha-Synuclein locus  triplication  causes  Parkinson's  disease. 
Science 2003;302(5646):841. 
25.  Chartier-Harlin  MC,  Kachergus  J,  Roumier  C,  Mouroux  V, 
Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan 
M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A. 
Alpha-synuclein  locus  duplication  as  a  cause  of  familial 
Parkinson's disease. Lancet 2004;364(9440):1167-1169. 
26.  Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak 
P,  Agid  Y,  Durr  A,  Brice  A.  Causal  relation  between 
alpha-synuclein  gene  duplication  and  familial  Parkinson's 
disease. Lancet 2004;364(9440):1169-1171. 
27.  Igaz  LM,  Kwong  LK,  Lee  EB,  Chen-Plotkin  A,  Swanson  E, 
Unger T, Malunda J, Xu Y, Winton MJ, Trojanowski JQ, Lee 
VM. Dysregulation of the ALS-associated gene TDP-43 leads to 
neuronal  death  and  degeneration  in  mice.  J  Clin  Invest 
2011;121(2):726-738. 
28.  Shan X, Chiang PM, Price DL, Wong PC. Altered distributions 
of Gemini of coiled bodies and mitochondria in motor neurons 
of  TDP-43  transgenic  mice.  Proc  Natl  Acad  Sci  U  S  A 
2010;107(37):16325-16330. 
29.  Stallings NR, Puttaparthi K, Luther CM, Burns DK, Elliott JL. 
Progressive  motor  weakness  in  transgenic  mice  expressing 
human TDP-43. Neurobiol Dis 2010;40(2):404-414. 
30.  Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 
mutant  transgenic  mice  develop  features  of  ALS  and 
frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 
2009;106(44):18809-18814. 
31.  Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, 
Smits  V,  Ceuterick-de  Groote  C,  Van  Broeckhoven  C, 
Kumar-Singh  S.  TDP-43  transgenic  mice  develop  spastic 
paralysis  and  neuronal  inclusions  characteristic  of  ALS  and 
frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 
2010;107(8):3858-3863. 
32.  Zhou  H,  Huang  C,  Chen  H,  Wang  D,  Landel  CP,  Xia  PY, 
Bowser  R,  Liu  YJ,  Xia  XG.  transgenic  rat  model  of 
neurodegeneration caused by mutation in the TDP gene. PLoS 
Genet 2010;6(3):e1000887. 
33.  Tatom JB, Wang DB, Dayton RD, Skalli O, Hutton ML, Dickson 
DW,  Klein  RL.  Mimicking  Aspects  of  Frontotemporal  Lobar 
Degeneration  and  Lou  Gehrig's  Disease  in  Rats  via  TDP-43 
Overexpression. Molecular Therapy 2009;17(4):607-613. 
34.  Thiruchelvam MJ, Powers JM, Cory-Slechta DA, Richfield EK. 
Risk  factors  for  dopaminergic  neuron  loss  in  human 
alpha-synuclein  transgenic  mice.  Eur  J  Neurosci 
2004;19(4):845-854. 
35.  Zhou H, Huang C, Yang M, Landel CP, Xia PY, Liu YJ, Xia XG. 
Developing tTA Transgenic Rats for Inducible and Reversible 
Gene Expression. Int J Biol Sci 2009;2(5):171-181. 
36.  Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, 
Gainetdinov  RR,  Caron  MG,  Di  Monte  DA,  Federoff  HJ. 
Behavioral and neurochemical effects of wild-type and mutated 
human  alpha-synuclein  in  transgenic  mice.  Exp  Neurol 
2002;175(1):35-48. 
37.  Xia  XG,  Zhou  H,  Huang  Y,  Xu  Z.  Allele-specific  RNAi 
selectively  silences  mutant  SOD1  and  achieves  significant 
therapeutic benefit in vivo. Neurobiol Dis 2006;23(3):578-586.  
38.  Zhou H, Falkenburger BH, Schulz JB, Tieu K, Xu Z, Xia XG. 
Silencing  of  the  Pink1  gene  expression  by  conditional  RNAi 
does not induce dopaminergic neuron death in mice. Int J Biol 
Sci 2007;3(4):242-250. 
39.  Huang C, Zhou H, Tong J, et al. FUS Transgenic Rats Develop 
the  Phenotypes  of  Amyotrophic  Lateral  Sclerosis  and Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
243 
Frontotemporal  Lobar  Degeneration.  PLOS  Genetics  2011;in 
press. 
40.  Niwa  H,  Yamamura  K,  Miyazaki  J.  Efficient  selection  for 
high-expression transfectants with a novel eukaryotic vector. 
Gene 1991;108(2):193-199. 
41.  Novak A, Guo C, Yang W, Nagy A, Lobe CG. Z/EG, a double 
reporter mouse line that expresses enhanced green fluorescent 
protein  upon  Cre-mediated  excision.  Genesis 
2000;28(3-4):147-155. 
42.  Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi 
MC,  Chou  TT,  Bruce  J,  Schuck  T,  Grossman  M,  Clark  CM, 
McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, 
et  al.  Ubiquitinated  TDP-43  in  frontotemporal  lobar 
degeneration  and  amyotrophic  lateral  sclerosis.  Science 
2006;314(5796):130-133. 
43.  Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, 
Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 
is a component of ubiquitin-positive tau-negative inclusions in 
frontotemporal  lobar  degeneration  and  amyotrophic  lateral 
sclerosis. Biochem Biophys Res Commun 2006;351(3):602-611. 
44.  Benajiba L, Le Ber I, Camuzat A, Lacoste M, Thomas-Anterion 
C, Couratier P, Legallic S, Salachas F, Hannequin D, Decousus 
M, Lacomblez L, Guedj E, Golfier V, Camu W, Dubois B, et al. 
TARDBPmutations in motoneuron disease with frontotemporal 
lobar degeneration. Annals of Neurology 2009;65(4):470-473. 
45.  Igaz LM, Kwong LK, Chen-Plotkin A, Winton MJ, Unger TL, Xu 
Y,  Neumann  M,  Trojanowski  JQ,  Lee  VM.  Expression  Of 
TDP-43 C-terminal fragments in vitro recapitulates pathological 
features  of  TDP-43  proteinopathies.  J  Biol  Chem  2009  Mar 
27;284(13):8516-24. 
46.  Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, 
Smits  V,  Ceuterick-de  Groote  C,  Van  Broeckhoven  C, 
Kumar-Singh  S.  TDP-43  transgenic  mice  develop  spastic 
paralysis  and  neuronal  inclusions  characteristic  of  ALS  and 
frontotemporal lobar degeneration. Proceedings of the National 
Academy of Sciences 2010;107(8):3858-3863. 
47.  Li Y, Ray  P, Rao  EJ,  Shi C,  Guo  W, Chen  X,  Woodruff  EA, 
Fushimi  K,  Wu  JY.  A  Drosophila  model  for  TDP-43 
proteinopathy.  Proceedings  of  the  National  Academy  of 
Sciences 2010;107(7):3169-3174. 
48.  Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 
mutant  transgenic  mice  develop  features  of  ALS  and 
frontotemporal lobar degeneration. Proceedings of the National 
Academy of Sciences 2009;106(44):18809-18814. 
49.  Iguchi  Y,  Katsuno  M,  Niwa  J,  Yamada  S,  Sone  J,  Waza  M, 
Adachi  H,  Tanaka  F,  Nagata  K,  Arimura  N,  Watanabe  T, 
Kaibuchi K, Sobue G. TDP-43 depletion induces neuronal cell 
damage through dysregulation of Rho family GTPases. J Biol 
Chem 2009;284(33):22059-22066.  
50.  Kabashi E, Lin L, Tradewell ML, Dion PA, Bercier V, Bourgouin 
P, Rochefort D, Bel Hadj S, Durham HD, Velde CV, Rouleau 
GA,  Drapeau  P.  Gain  and  loss  of  function  of  ALS-related 
mutations of TARDBP (TDP-43) cause motor deficits in vivo. 
Hum Mol Genet 2009;18:18. 
51.  Feiguin F, Godena VK, Romano G, D'Ambrogio A, Klima R, 
Baralle  FE.  Depletion  of  TDP-43  affects  Drosophila 
motoneurons terminal synapsis and locomotive behavior. FEBS 
Lett 2009;583(10):1586-1592.  
52.  Chiang PM, Ling J, Jeong YH, Price DL, Aja SM, Wong PC. 
Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to 
obesity, and alters body fat metabolism. Proc Natl Acad Sci U S 
A 2010;107(37):16320-16324. 
53.  Wu  LS,  Cheng  WC,  Hou  SC,  Yan  YT,  Jiang  ST,  Shen  CK. 
TDP-43,  a  neuro-pathosignature  factor,  is  essential  for  early 
mouse embryogenesis. Genesis 2010;15:15. 
54.  Hikida T, Jaaro-Peled H, Seshadri S, Oishi K, Hookway C, Kong 
S, Wu D, Xue R, Andrade M, Tankou S, Mori S, Gallagher M, 
Ishizuka  K,  Pletnikov  M,  Kida  S,  et  al.  Dominant-negative 
DISC1  transgenic  mice  display  schizophrenia-associated 
phenotypes detected by measures translatable to humans. Proc 
Natl Acad Sci U S A 2007;104(36):14501-14506.  
55.  Lai C, Lin X, Chandran J, Shim H, Yang W, Cai H. The G59S 
mutation  in  p150(glued)  causes  dysfunction  of  dynactin  in 
mice. J Neurosci 2007;27(51):13982-13990. 
56.  Kudo T, Kure S, Ikeda K, Xia AP, Katori Y, Suzuki M, Kojima K, 
Ichinohe  A,  Suzuki  Y,  Aoki  Y,  Kobayashi  T,  Matsubara  Y. 
Transgenic  expression  of  a  dominant-negative  connexin26 
causes degeneration of the organ of Corti and non-syndromic 
deafness. Hum Mol Genet 2003;12(9):995-1004. 
57.  Cairns  NJ,  Neumann  M,  Bigio  EH,  Holm  IE,  Troost  D, 
Hatanpaa KJ, Foong C, White CL, Schneider JA, Kretzschmar 
HA,  Carter  D,  Taylor-Reinwald  L,  Paulsmeyer  K,  Strider  J, 
Gitcho M, et al. TDP-43 in familial and sporadic frontotemporal 
lobar  degeneration  with  ubiquitin  inclusions.  Am  J  Pathol 
2007;171(1):227-240. 
58.  Leverenz  JB,  Yu  CE,  Montine  TJ,  Steinbart  E,  Bekris  LM, 
Zabetian C, Kwong LK, Lee VM, Schellenberg GD, Bird TD. A 
novel  progranulin  mutation  associated  with  variable  clinical 
presentation and tau, TDP43 and alpha-synuclein pathology. 
Brain 2007;130(Pt 5):1360-1374. 
59.  Josephs  KA,  Ahmed  Z,  Katsuse  O,  Parisi  JF,  Boeve  BF, 
Knopman DS, Petersen RC, Davies P, Duara R, Graff-Radford 
NR, Uitti RJ, Rademakers R, Adamson J, Baker M, Hutton ML, 
et  al.  Neuropathologic  features  of  frontotemporal  lobar 
degeneration  with  ubiquitin-positive  inclusions  with 
progranulin  gene  (PGRN)  mutations.  J  Neuropathol  Exp 
Neurol 2007;66(2):142-151. 
60.  Yokota  O,  Davidson  Y,  Arai  T,  Hasegawa  M,  Akiyama  H, 
Ishizu H, Terada S, Sikkink S, Pickering-Brown S, Mann DM. 
Effect of topographical distribution of α-synuclein pathology 
on  TDP-43  accumulation  in  Lewy  body  disease.  Acta 
Neuropathol 2010;120(6):789-801. 